Feb 18, 2020
Phosplatin Therapeutics Announces Publication in OncoImmunology
Feb 04, 2020
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
Jan 29, 2020
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
Jan 09, 2020
Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde
Jan 08, 2020
Pancreatic Cancer Cells Secrete Signal that Sabotages Immune Attack on Tumors
Jan 07, 2020
Beta Lifescience Announces the Online Availability of Quality Immune Checkpoint Proteins for Scientific Discoveries
Jan 07, 2020
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
Dec 19, 2019
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
Dec 16, 2019
iOmx Therapeutics to Present at Biotech Showcase 2020
Dec 12, 2019
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Nov 21, 2019
iOmx Therapeutics' iOTarg(TM) Genetic Screening Platform Featured in Podium Presentation at PEGS Europe 2019
Nov 12, 2019
Agenus to Host R&D Day November 15, 2019
Nov 12, 2019
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
Nov 11, 2019
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
Nov 11, 2019
Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting
Nov 06, 2019
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
Nov 06, 2019
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
Nov 05, 2019
Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
Nov 04, 2019
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
Nov 04, 2019
Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting